Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Acute Lymphoblastic Leukemia Maggie Davis Hovda 5/26/2009 Definition Neoplastic disease which results from a mutation in a single lymphoid progenitor cell at one of several discrete stages of development B Cell or T Cell Epidemiology Most common childhood acute leukemia, ~80% Incidence in adults ~20% Bimodal distribution of occurrence: Peak at age 2-5 Second increased incidence after age 50 Pathogenesis Acquired Genetic Change in Chromosome Change in number, ie ploidy Change in structure Translocations (most common) Inversions Deletions Point mutations Amplifications Changes in normal means of cell differentiation, proliferation, and survival Mechanisms of Leukemia Induction 1 – Activation of a protooncogene OR creation of a fusion gene with oncogenic properties - Ph Chromosome t(9;22) 2 – Loss or inactivation of ≥ 1 tumor suppressor gene - p53 (p16 mutation) Etiology Unknown ? Genetic Predisposition Down Syndrome Disorder with chromosomal fragility: Increased incidence amongst monozygotic and dizygotic twins Fanconi’s anemia Bloom Syndrome Ataxia-Telangiectasia ? Infections HTLV1 in T cell leukemia/lymphoma EBV in mature B cell ALL HIV in lymphoproliferative DO Presentation Nonspecific Symptoms Fatigue/decreased energy Fever Easy bruising Bleeding Dyspnea Dizziness Infection Joint, extremity pains CNS involvement Clinical Presentation Physical Exam Lab Abnormalities Pallor anemia Ecchymoses wbc Petechiae LAD Hepatosplenomegaly 0.1 (20-40%) - >100 k (10-16%) Platelets – usually ↓ ↑ LD, uric acid CXR: eval for thymic mass CSF to eval for involvement vary Diagnosis Morphologic French American British Classification L1: small uniform blasts (pediatric ALL) L2: larger, more variable sized blasts (adult ALL) L3: uniform cells with basophilic and sometimes vacuolated cytoplasm (mature B cell ALL) Immunophenotyping From: Jabbour, E. et al. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527 Cytogenetic Abnormalities From: Jabbour, E. et al. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527 Classification of ALL Immunologic Subtype % of cases FAB Subtype Cytogenetic Abnormalities Pre-B ALL 75 L1, L2 t(9;22), t(4;11), t(1;19) T cell ALL 20 L1, L2 14q11 or 7q34 B cell ALL 5 L3 t(8;14), t(8;22), t(2;8) From: Harrison’s Principles of Internal Medicine, 16th ed. 2005. Chapter 97, Malignancies of lymphoid cells. Differential Diagnosis ITP Aplastic Anemia Infectious mononucleosis Rheumatoid Arthritis Rheumatic Fever Collagen Vascular Disease Treatment 1 – Remission Induction 2 – Intensification (Consolidation) Therapy 3 – Maintenance Therapy 4 – CNS Prophylaxis 5 – Allogeneic Stem Cell Transplant Treatment Remission Induction Goals: restore normal hematopoiesis, induce a complete remission rapidly in order to prevent resistance to drugs Standard induction regimen 4 or 5 drugs: vincristine, prednisone, anthracycline, Lasparaginase, +/- cyclophosphamide Intensification High doses of multiple agents not used during induction or re-administration of the induction regimen Treatment Maintenance Therapy Daily po 6MP, weekly MTX, monthly pulses of vincristine and prednisone for 2-3 yrs CNS Prophylaxis Given during induction and intensification Intrathecal: MTX, Cytarabine, corticosteroids Systemic: high dose mtx, cytarabine, L-asparaginase +/- Cranial Irradiation Treatment Stem Cell Transplant Done during first CR Indications: Ph Chromosome t(4;11) mutation Poor initial response to induction therapy Other Adolescents benefit significantly from pediatric ALL regimens vs. adult regimens Relapse & Prognosis Relapse Most occur during treatment or within the first 2 years Bone Marrow is the most common site Poor prognostic factors in patients previously treated: Relapse on therapy Short initial remission after intense therapy T-cell immunophenotype Ph Chromosome Circulating blasts High leukocyte count at relapse Prognosis Overall better in children than in adults In adults, worse outcomes with: Increasing age, >60 Increased wbc count at presentation Sources Jabbour, E. et al. Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527 Xavier, T. Chemotherapy of acute leukemia in adults. Expert Opin. Pharmacother. (2009) 10(2):221-237 Williams Hematology, 6th ed. 2001. Chapter 97, Acute Lymphoblastic Leukemia. Harrison’s Principles of Internal Medicine, 16th ed. 2005. Chapter 97, Malignancies of lymphoid cells.